ARNS partners and exhibitors have had no input into the agenda of the conference, apart from sponsored symposia.
Thank you to all our 2024 Partners:
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its medicines are used by millions of patients worldwide.
With a proud 100-year heritage in advancing UK science, today AstraZeneca is the UK’s leading biopharmaceutical company. The company is based in five different locations across the UK, with its global headquarters in Cambridge. In the UK, around 8,700 employees work in research and development, manufacturing, supply, sales, and marketing. We supply around 36 different medicines to the NHS.
For more information, please visit www.astrazeneca.co.uk and follow us on Twitter @AstraZenecaUK.
Boehringer Ingelheim has over 100 years of heritage in respiratory disease.
Since 1921 we have emerged as a leader in this disease area, having developed and launched treatments for a range of respiratory conditions including lung cancer, asthma, chronic obstructive pulmonary disease (COPD), treatment of adults with idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
Our continued focus is on improving the life of patients suffering from debilitating respiratory diseases.
PC-GB-105963 V2 Date of preparation; September 2023
Boehringer Ingelheim has provided financial support to ARNS as a partnership for 2024. The funding enabled ARNS to provide ongoing education and development for respiratory nurses. Boehringer Ingelheim has had no input into ARNS activities other than an exhibition stand and a symposium slot at the annual conference.
Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused biopharmaceuticals group with over 85 years’ experience in the pharmaceutical sector operating in 30 countries, employing around 6,000 people. Chiesi develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. Chiesi Limited is headquartered in Manchester employing over 400 people.
GSK are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.
NP-GB-RS-COCO-230002 | January 2024
A global leader in interventional pulmonology, planning tools, and treatments for obstructive lung disease.
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is the maker of the Zephyr Endobronchial Valve. The Zephyr® Valve was granted breakthrough status and approved by the FDA in June 2018, because according to the FDA it “represents a breakthrough technology as the device offers bronchoscopic lung volume reduction without surgery and its associated risks. This device offers a significant, clinically meaningful advantage over the current standard of care and therefore, its availability is also in the best interest of patients.”
The company’s commercially available portfolio includes the Zephyr Endobronchial Valve. More than 100 scientific articles have been published on the clinical benefits of Zephyr Valves, including multiple meta-analyses, review articles, cost-effectiveness analyses and risk-benefit analyses.
Thank you to all our Exhibitors:
Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. We are powered by purpose, a purpose to serve patients and their families with unwavering dedication. A purpose to find solutions where there were none before. A purpose to do what’s right, even when it isn’t easy.
A biotech company that empowers great people to deliver with a profound sense of urgency and compassion, life-altering therapies to small patient populations experiencing big health problems, transforming the lives of patients living with serious and rare diseases.
At Insmed, we are powered by our shared sense of purpose to serve patients. We don’t always have a defined play book, but we operate with passion and creativity to find the best path forward. We take pride in our ability to challenge the status quo. Team members are comfortable operating outside their traditional roles and comfort zones, using what we already know to uncover what we don’t.
Manufacturing respiratory devices for over 100 years. A wealth of experience supporting health providers to assess, diagnose and manage respiratory conditions with our range of high-quality, hand-calibrated devices - all made in the UK for accuracy and reassured efficacy on treating patients with the best course of care.
A complete range of natural products for the treatment and prevention of allergic symptoms, caused by airborne allergens such as pollen, house dust, or animal dander.
Irwin Mitchell’s reputation for helping clients and their families with a wide range of personal legal issues is second to none. Our highly specialised team combines powerful legal knowledge and experience with care and consideration to ensure that clients receive the best possible support & guidance throughout their claim and beyond.
- lee.simpson@irwinmitchell.com
- www.irwinmitchell.com
- 07917 287 705
Trudell Medical International works with patients, their caregivers and healthcare professionals to help patients all over the world breathe better and fuller lives. We manufacture and globally market some of the leading brands in respiratory care including the AeroChamber* brand of spacers, Aerobika* OPEP devices, and AeroEclipse* BAN* nebulisers
Lupin Healthcare are proud to provide high quality medicines to patients that deliver both quality and value to the NHS.
Today’s portfolio consists of Respiratory and Neuromuscular medicines and high quality generics with a focus on anti-retroviral and oral contraceptives.
Hodge Jones & Allen solicitors, founded in 1977, help their clients assert and defend their rights, and resolve personal legal matters to achieve the best possible outcome.
Our national Asbestos and Industrial Disease Team, based in London, Wales and NW England, is led by Partner, Isobel Lovett. With Partners, Lorna Webster and Lyndsey Gordon-Webb, the trio have over 60 years’ combined experience in representing victims of mesothelioma and other asbestos and work-related respiratory illnesses.
Our bespoke service to patients includes: home visits, enabling access to state benefits, navigating the legal process and signposting to support groups. In addition to achieving maximum compensation settlements, we routinely secure payment from Defendants’ insurers, for non-NHS funded treatment, in suitable cases.
Our team are hugely proud to support and work alongside Respiratory and Lung Cancer Nurse specialists, other medical professionals and asbestos support groups, to provide the specialist service needed by those affected by asbestos and other work-related respiratory conditions.
Ranked by Chambers UK Legal Guide, in 2024 – “The team are diligent, persistent and professional throughout. Their communication is exceptional.”
Isobel Lovett is recognised by Legal 500 as “a first-rate litigator” who will “pull out all the stops” for her clients, and by Chambers as “very empathetic” and “having considerable experience and a determination to do the best for her clients”.
Our mission is to improve patients’ lives by providing market leading products and services. Our intention is to have an impact in the effective management of respiratory diseases. We provide a wide variety of precise, intuitive devices for respiratory care including spirometers, lung & asthma monitors, COPD screeners, ECG, FeNO, and medical workstations as well as software and consumables.
We are excited to showcase our next generation PC-based, desktop and handheld spirometers. Compliant with the 2019 ATS/ERS spirometry update, these devices ensure your service meets the latest international guidelines on accuracy and reporting. Their brand-new intuitive interfaces automatically grade tests and provide quality control feedback for easy and rapid testing.
For further peace of mind these come with FREE 5 YEAR WARRANTY and FREE ONLINE DEVICE TRAINING and FREE CONNECT electronic medical record interface software.
Protect your patients, staff, and equipment with an Eco BVF™, suitable for most leading brands of spirometers. Independently validated 99.999% bacterial and viral cross-contamination efficiency, these filters are made using less plastic, are lighter to transport, and are made from 100% recyclable materials.
Our friendly and knowledgeable experts will be available throughout the conference to chat about your needs.
Visit www.vitalograph.co.uk or call 01280 827110.
The aim of the Pulmonary Fibrosis Trust is to provide personal support to people affected by pulmonary fibrosis, a very debilitating and life-limiting illness.
We offer practical, emotional and financial support where there is a need. We also raise awareness of the illness and in particular the challenges people face on a daily basis.
The Pulmonary Fibrosis Trust was founded by patients who experienced a lack of information and support upon their own diagnosis, and therefore, wanted to support others through this process.
We are here to support all those affected by pulmonary fibrosis, whether you are a sufferer or have a loved one with pulmonary fibrosis.
Whether you call, email or connect with us via social media, there will always be an understanding, listening ear.
Many of our trustees have pulmonary fibrosis themselves and are always willing to provide emotional support by listening and sharing experiences, such as, journey to diagnosis and treatment options. Speaking with someone who is going through a similar journey can be extremely beneficial, they can fully understand your questions, uncertainties and worries.
The Pulmonary Fibrosis Trust can provide funding for essential equipment to support sufferers in gaining their independence. Previously, funding has been provided for equipment such as additional batteries for portable oxygen concentrators, wheelchairs, mobility scooters and stairlifts.
As part of our ongoing commitment to improve the lives of sufferers we can now offer short breaks for PF sufferers and their families in our caravan in Great Yarmouth.
The Pulmonary Rehabilitation Services Accreditation Scheme (PRSAS) was launched in April 2018. The aim of the programme is to improve the quality of pulmonary rehabilitation services throughout the UK. The Pulmonary Rehabilitation Services Accreditation Scheme (PRSAS) is run by the Royal College of Physicians (RCP). The Pulmonary Rehabilitation audit, also managed and delivered by the RCP, is part of the National Respiratory Audit Programme (NRAP) and is commissioned by the Healthcare Quality Improvement Partnership (HQIP).